United Kingdom
Cytomos, founded in 2012, is a UK-based company operating at the intersection of Biopharma, Biotechnology, and Machine Learning. The company has developed a unique cell analytics technology, AuraCyt™, which offers predictive analytics for suspended cells. This innovative tool provides unbiased insights that are beneficial from initial R&D stages to full-scale manufacturing.
With the slogan "Prompt and predictive cell analytics that scale from R&D to manufacture," Cytomos highlights its key value proposition. AuraCyt™ stands to disrupt traditional cytometry by delivering rapid, scalable solutions that streamline the drug development process while minimizing inefficiencies.
In August 2023, Cytomos secured a substantial £4.00M Series A investment. Key investors in this round included Scottish Enterprise, Archangel Investors Limited, British Business Bank, and Edinburgh Innovations, signaling strong confidence in the company's growth trajectory and technological promise.
